Price Don’t Lie: Could Teva Pharmaceutical Industries Ltd (ADR) Go Up After Achieving 1 Year Low?

Price Don't Lie: Could Teva Pharmaceutical Industries Ltd (ADR) Go Up After Achieving 1 Year Low?

The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) hit a new 52-week low and has $35.87 target or 5.00% below today’s $37.76 share price. The 9 months bearish chart indicates high risk for the $37.80B company. The 1-year low was reported on Nov, 23 by Barchart.com. If the $35.87 price target is reached, the company will be worth $1.89 billion less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 893,454 shares traded hands. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 33.92% since April 21, 2016 and is downtrending. It has underperformed by 39.25% the S&P500.

Analysts await Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to report earnings on February, 9. They expect $1.39 earnings per share, up 8.59% or $0.11 from last year’s $1.28 per share. TEVA’s profit will be $1.39B for 6.79 P/E if the $1.39 EPS becomes a reality. After $1.28 actual earnings per share reported by Teva Pharmaceutical Industries Ltd (ADR) for the previous quarter, Wall Street now forecasts 8.59% EPS growth.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Ratings Coverage

Out of 22 analysts covering Teva Pharma (NYSE:TEVA), 13 rate it a “Buy”, 0 “Sell”, while 9 “Hold”. This means 59% are positive. Teva Pharma has been the topic of 40 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Jefferies reinitiated the stock with “Buy” rating in Friday, October 30 report. On Wednesday, November 16 the stock rating was maintained by Mizuho with “Neutral”. The rating was upgraded by Goldman Sachs on Monday, November 23 to “Buy”. On Wednesday, November 16 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. The company was initiated on Thursday, September 29 by OTR Global. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, July 29. The rating was reinitiated by JP Morgan with “Overweight” on Monday, August 3. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Overweight” rating by Morgan Stanley on Tuesday, May 3. The company was maintained on Thursday, July 14 by Jefferies. The stock has “Neutral” rating given by Bank of America on Monday, November 7.

According to Zacks Investment Research, “TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.”

Another recent and important Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) news was published by Investorplace.com which published an article titled: “Why Nokia Corp (ADR) (NOK), Teva Pharmaceutical Industries Ltd (ADR) (TEVA …” on November 15, 2016.

TEVA Company Profile

Teva Pharmaceutical Industries Limited, incorporated on February 13, 1944, is a global pharmaceutical company. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Firm operates through two divisions: Generic medicines and Specialty medicines. The Firm has a global portfolio of approximately 1,000 molecules.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment